Investor Relations

Press Releases

Press Releases

Aug 28, 2019
Karuna Therapeutics to Present at Upcoming Investor Conferences
BOSTON --(BUSINESS WIRE)--Aug. 28, 2019-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled
Apr 01, 2019
Karuna Completes $80 Million Series B Financing
$12 million in extension funding announced Karuna awarded U.S. Patent covering lead product candidate, KarXT BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc . (“Karuna”) focused on targeting muscarinic receptors for the treatment of neuropsychiatric disorders, including psychosis in
Mar 18, 2019
Karuna Announces $68 Million Series B Financing
Proceeds will be used to advance clinical development of lead product candidate, KarXT, for additional indications beyond the ongoing Phase 2 clinical trial in schizophrenia and for expansion of the pipeline BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc.
Mar 13, 2019
Karuna Bolsters Research and Development Team
BOSTON--( BUSINESS WIRE )-- Karuna Pharmaceuticals, Inc.  (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, as well as pain, today announced the appointment of Christian (Chris) Felder,
Top